<DOC>
	<DOCNO>NCT01714817</DOCNO>
	<brief_summary>The purpose study evaluate ( Abatacept ) treatment lupus nephritis use background Cellcept ( mycophenolate ) prednisone ( corticosteroid )</brief_summary>
	<brief_title>Efficacy Safety Study Abatacept Treat Lupus Nephritis</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>For additional information please contact BMS Lupus Nephritis Clinical Trial Matching Service 85556LUPUS . Please visit www.BMSStudyConnect.com information clinical trial participation . Note : Subjects &gt; 16 eligible enrollment select center Potential subject must active lupus nephritis Biopsy within 12 month prior screen visit indicate active Class 3 4 proliferative lupus glomerulonephritis ( lupus effect kidney ) Urine protein creatinine ratio ( UPCR ) ≥ 1 Screening Serum creatinine ≤ 3 mg/dL ( ie , ≤ 265 micromol/L ) There must also evidence active disease within 3 month Screening , base least one following : Worsening lupus nephritis OR UPCR ≥ 3 Screening OR Active urine sediment OR Biopsy within 3 month prior screen visit indicate active Class 3 Class 4 active proliferative lupus glomerulonephritis Inclusion Criteria LongTerm Extension Period : Signed Written Informed Consent Subjects achieve complete partial renal response complete 2 year doubleblind treatment Systemic Lupus Erythematosus ( SLE ) must primary/main autoimmune diagnosis Current symptom severe , progressive , uncontrolled nonSLE related renal , hepatic , hematological , gastrointestinal , pulmonary , cardiac , neurological , cerebral disease , concomitant medical condition , opinion Investigator , might place subject unacceptable risk participation study Significant active Central nervous system ( CNS ) lupus exception fatigue mild stable cognitive Subjects diagnose endstage renal disease whose kidney damage significant irreversible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>